A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Adults With HIV-1 Infection
Latest Information Update: 23 May 2025
At a glance
- Drugs STP-0404 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors ST Pharm
Most Recent Events
- 02 Dec 2024 Planned End Date changed from 21 Nov 2024 to 31 Dec 2025.
- 02 Dec 2024 Planned primary completion date changed from 21 Oct 2024 to 10 Dec 2025.
- 10 Mar 2024 Planned End Date changed from 13 May 2024 to 21 Nov 2024.